Sort
82,697 grants matching “vaccine development”
Clinical trials employing cancer vaccine combination therapies
$846,484James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Cancer Therapy Clinical Trials Using Novel Recombinant Vaccines
$846,484James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Characterization of Persistent COVID-19
$846,387Jonathan Li · Brigham And Women'S Hospital · R01 · FY2024 · AI
Development of the Next Generation of Conjugate Vaccines
$846,375Luc Teyton · Scripps Research Institute, The · R01 · FY2019 · AI
Vaccine Development Of Nontypeable Haemophilus influenzae/Moraxella catarrhalis
$846,275Xin-Xing Xing Gu · National Institute On Deafness And Other Communication Disorders · ZIA · FY2009 · DC
Determinants of HIV-1 innate immune sensing and its role in shaping the lymphoid environment.
$846,223Sunnie Yoh · Scripps Research Institute, The · R01 · FY2025 · AI
Development of novel HIV Env vaccines to augment B lymphocyte responses via delivery of stabilized well-ordered Env spikes for comparative evaluation in preclinical immunogenicity and efficacy studies
$845,995Christopher Parks · International Aids Vaccine Initiative · P01 · FY2016 · AI
Task 13/C26: Influenza Challenge Models and Assays for Influenza Vaccines
$845,992Southern Research Institu · N01 · FY2012 · AI
Task A71: Evaluation of Therapeutics and Vaccines in Mouse Models of Dengue Virus
$845,987Alan D.t. Barrett · University Of Texas Med Br Galveston · N01 · FY2015 · AI
Using immune complex vaccines to optimize antibody responses to HIV Env
$845,905Catarina E Hioe · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · AI
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
$845,852Joseph Patti · Agilvax, Inc. · R44 · FY2019 · CA
Development testing of nucleic acid-based vaccine for HIV other indications
$845,848Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
PROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA
$845,841Chinthalapally Rao · University Of Oklahoma Hlth Sciences Ctr · N01 · FY2021 · CA
Mechanisms Underlying Persistent Lentivirus Replication in Follicular T Cells
$845,761Elizabeth Connick · University Of Colorado Denver · R01 · FY2015 · AI
Cytolytic antibodies:Bridging the gap between the innate and adaptive immune resp
$845,738Galit Alter · Massachusetts General Hospital · R01 · FY2012 · AI
Characterization of Persistent COVID-19
$845,667Jonathan Li · Brigham And Women'S Hospital · R01 · FY2025 · AI
Host-pathogen interactions during hospital adaptation of MRSA
$845,624Bo Shopsin · New York University School Of Medicine · R01 · FY2019 · AI
Preclinical Development of PS-26 - an Oxybiguanide
$845,597Jacobus Pharmaceutical Company, Inc. · R44 · FY2003 · AI
Infection-blocking antibody targets for malaria
$845,571Stefan H.i. Kappe · Seattle Children'S Hospital · R01 · FY2019 · AI
SOUTHERN AFRICA-NEW YORK HIV VACCINE TRIALS UNIT
$845,499Medical Research Council Of South Africa · U01 · FY2003 · AI
Using immune complex vaccines to optimize antibody responses to HIV Env
$845,474Catarina E Hioe · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · AI
Microarray Patch for Broadly Protective Seasonal Influenza Vaccination
$845,449Kathryn Kosuda · Vaxess Technologies, Inc. · SB1 · FY2023 · AI
The MW Cancer Prevention Clinical Trials Network
$845,369Howard H Bailey · University Of Wisconsin-Madison · UG1 · FY2020 · CA
Project 2: Design and screening for immunogens to efficiently elicit anti-HIV-1 bNAbs
$845,350Pamela J Bjorkman · California Institute Of Technology · P01 · FY2020 · AI
Multi-center Evaluation of the Threat of Established and Emerging Respiratory Viral Infections in Pediatric Transplant Recipients
$845,245William J Steinbach · Arkansas Children'S Hospital Res Inst · R01 · FY2022 · AI